Spots Global Cancer Trial Database for hematological malignancy
Every month we try and update this database with for hematological malignancy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product | NCT05768269 | Hematological M... Solid Tumor Mal... | No Intervention | 18 Years - | Century Therapeutics, Inc. | |
| Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia | NCT01025778 | Acute Lymphobla... Acute Myeloid L... | Clofarabine for... Etoposide for r... Cyclophosphamid... Clofarabine in ... Thiotepa in con... Melfalan in con... Haploidentical ... Donor lymphocyt... | 1 Year - 21 Years | Lund University Hospital | |
| A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation | NCT00894049 | Allograft Allogeneic Cell... Hematological M... Solid Tumor | reduced intensi... | 18 Years - 65 Years | Institut Paoli-Calmettes | |
| Individual Dietary Counseling Based on Taste-tests in Patients With Hematological Cancer in Cytostatic Therapy | NCT05364359 | Hematological M... | Taste-test Standard care | - | University of Copenhagen | |
| Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) | NCT02186821 | Tumors With Abe... | Ceritinib | 18 Years - | Novartis | |
| Prospective Clinical Evaluation of Beta-D-Glucan Assay in Blood and BAL | NCT01576653 | Invasive Fungal... Hematological M... Receipt of Soli... | Fungitell Assay... | 18 Years - 95 Years | Medical University of Graz | |
| Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis | NCT02213822 | Solid Tumors Hematological M... | Molecular Analy... | 18 Years - | Rhode Island Hospital | |
| Use of nMoABs for the Treatment of COVID-19 in Patients With HM. | NCT04932967 | Covid19 Hematological M... | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | ||
| Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence | NCT04663100 | Chronic Myeloid... Chronic Lymphoc... Multiple Myelom... Multiple Chroni... | Patient-reporte... Comprehensive M... Pharmacist comm... | 18 Years - | University of Tennessee | |
| Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation | NCT03159702 | Hematological M... Multiple Myelom... | Evomela Fludarabine Total Body Irra... | 18 Years - | Medical College of Wisconsin | |
| A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients | NCT03241550 | Hematological M... | isavuconazonium... isavuconazonium... | 1 Year - 17 Years | Astellas Pharma Inc | |
| Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients | NCT00195533 | Hematological M... Leukemia Myelodysplasia Lymphoma Myeloma Stem Cell Trans... | piperacillin-ta... glycopeptide | 18 Years - | Wyeth is now a wholly owned subsidiary of Pfizer | |
| First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors | NCT05828459 | Hematological M... Solid Tumor | OT-A201 IMids Bevacizumab Paclitaxel TBD Compound | 18 Years - | Onward Therapeutics | |
| First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors | NCT05828459 | Hematological M... Solid Tumor | OT-A201 IMids Bevacizumab Paclitaxel TBD Compound | 18 Years - | Onward Therapeutics | |
| An Open-label Phase II Study of Lorvotuzumab Mertansine | NCT02420873 | Leukemia | Lorvotuzumab Me... | 18 Years - | M.D. Anderson Cancer Center | |
| Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies | NCT01635712 | Cancer | SNX-5422 | 18 Years - | Esanex Inc. | |
| Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO | NCT02149329 | Febrile Neutrop... Hematological M... | Discontinuation... | 18 Years - | Amsterdam UMC, location VUmc | |
| PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients | NCT04243434 | Hematologic Dis... | Vincristine Sul... CHOP R-CHOP | 18 Years - | Acrotech Biopharma Inc. | |
| Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis | NCT02213822 | Solid Tumors Hematological M... | Molecular Analy... | 18 Years - | Rhode Island Hospital | |
| A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product | NCT05768269 | Hematological M... Solid Tumor Mal... | No Intervention | 18 Years - | Century Therapeutics, Inc. | |
| A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies | NCT04008524 | Relapsed and Re... | CAR-T cells | - | Institute of Hematology & Blood Diseases Hospital, China | |
| VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies | NCT03885947 | Hematological M... Acute Leukemia ... Acute Lymphobla... Myelodysplastic... Non-Hodgkin Lym... Hodgkin Lymphom... | Cord blood stem... Valproic Acid Fludarabine cytoxan Thiotepa TBI | 18 Years - 65 Years | Icahn School of Medicine at Mount Sinai | |
| The Effect of Music Therapy on Comfort, Pain and Anxiety | NCT05895357 | Bone Marrow Dis... Hematological M... | Musictherapy | 18 Years - 100 Years | Izmir Bakircay University | |
| Impact of a Monitoring Device for Patients With Cancer Treated Using Oral Therapeutics | NCT02828462 | Metastatic Canc... Hematological M... | CAPRI | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM) | NCT03875495 | Multiple Myelom... | Temferon | 18 Years - 70 Years | Genenta Science | |
| Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation | NCT01757145 | Hematological M... Bone Marrow Fai... | Eltrombopag | 18 Years - | Rabin Medical Center | |
| A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy | NCT00558675 | Hematological M... Leukemia Lymphoma Multiple Myelom... | AlloStim AlloStim AlloStim AlloStim | 18 Years - | Immunovative Therapies, Ltd. | |
| Ceritinib Rare Indications Study in ALK+ Tumors | NCT02465528 | Tumors With Abe... Anaplastic Larg... Inflammatory My... Glioblastoma | Ceritinib (LDK3... | 18 Years - | Novartis | |
| Use of nMoABs for the Treatment of COVID-19 in Patients With HM. | NCT04932967 | Covid19 Hematological M... | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | ||
| Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO | NCT02149329 | Febrile Neutrop... Hematological M... | Discontinuation... | 18 Years - | Amsterdam UMC, location VUmc | |
| Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO | NCT02149329 | Febrile Neutrop... Hematological M... | Discontinuation... | 18 Years - | Amsterdam UMC, location VUmc | |
| SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies | NCT04684108 | Relapsed or Ref... Hematological M... | SG301 | 18 Years - | Hangzhou Sumgen Biotech Co., Ltd. | |
| AMS Intervention for Early Adaptation of Empirical Antibiotic Therapy in High-risk Neutropenic Patients | NCT05793073 | Neutropenia | 18 Years - | Centre Hospitalier Universitaire de Nice | ||
| Prognosis of Hematological Cancer Patient Underwent Mechanical Ventillation | NCT02562105 | Hematological M... Acute Respirato... Mechanical Vent... | Mechanical vent... | 18 Years - 75 Years | Mansoura University | |
| A Study of Shengxuening Tablet in the Treatment of Chemotherapy-related Anemia in Hematologic Tumors | NCT05784870 | Hematological M... Cancer-Related ... | Shengxuening Ta... Ferrous succina... | 18 Years - | Zhongnan Hospital | |
| DxFLEX 10C Clinical Study | NCT05467449 | Hematological M... | DxFLEX 10C | - | Beckman Coulter, Inc. | |
| Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients | NCT00195533 | Hematological M... Leukemia Myelodysplasia Lymphoma Myeloma Stem Cell Trans... | piperacillin-ta... glycopeptide | 18 Years - | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Body Scan Activity on Bone Marrow Transplant Patients and Their Caregivers | NCT03611764 | Hematological M... | Body Scan Rotterdam Sympt... Practice Logs | - | Washington University School of Medicine | |
| HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib | NCT03850366 | Hematological M... | Bortezomib | 18 Years - 65 Years | Henry Ford Health System | |
| Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation | NCT02598752 | Acute Myeloid L... Myelodysplastic... Hematological M... Leukemia Lymphoma Myeloma | Symptom-limited... Resting assessm... Post-exercise a... Pulmonary funct... Patient-reporte... | 21 Years - | Memorial Sloan Kettering Cancer Center | |
| Tissue Microarray of Hematological Malignancies | NCT04142372 | Hematological M... | - | Tampere University Hospital | ||
| Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy | NCT04093622 | Hematological M... | Genetically eng... | 18 Years - | Fate Therapeutics | |
| Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials | NCT02534649 | Solid Tumor Hematological M... | Newly obtained ... | 18 Years - | Institut Bergonié | |
| Impact of a Monitoring Device for Patients With Cancer Treated Using Oral Therapeutics | NCT02828462 | Metastatic Canc... Hematological M... | CAPRI | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies | NCT06225856 | Advanced Solid ... Hematological M... | YY201 | 18 Years - 80 Years | Shanghai Yuyao Biotech Co., Ltd. | |
| Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19 | NCT04347226 | Solid Tumor Sars-CoV2 Hematological M... | BMS-986253 | 18 Years - | Columbia University | |
| Low-Flow vs. High-Flow Nasal Cannula for Hypoxemic Immunocompromised Patients During Diagnostic Bronchoscopy | NCT03168815 | Immunocompromis... Hematologic Mal... Post Hematopoie... Hypoxia Pulmonary Infil... | High Flow Nasal... | 18 Years - | Mount Sinai Hospital, Canada | |
| Effects of Periodized and Autoregulated Resistance Training in Haematological Cancer Patients During the Treatent. | NCT04406285 | Fatigue Leukemia Lymphoma Physical Disabi... | Standard protoc... Periodic Resist... Standard protoc... Periodic Resist... | 18 Years - 64 Years | Federal University of Health Science of Porto Alegre | |
| Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells | NCT00692926 | MDS Anemia, Aplasti... Inborn Errors o... Congenital Marr... Congenital Immu... | ALDHbr Umbilica... | - 55 Years | Duke University | |
| Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies | NCT04305249 | Solid Tumor Hematological M... | ATG-017 ATG-017+Nivolum... | 18 Years - | Antengene Corporation | |
| A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients | NCT03241550 | Hematological M... | isavuconazonium... isavuconazonium... | 1 Year - 17 Years | Astellas Pharma Inc | |
| First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | NCT04067336 | Advanced Malign... Acute Myeloid L... Mixed Lineage L... Mixed Lineage A... Acute Leukemia ... Mixed Phenotype... | Ziftomenib | 18 Years - | Kura Oncology, Inc. | |
| Treatment of Patients With Donor Lymphocytes Sensitized by Antigens Expressed by the Host | NCT00149032 | Hematological M... Neoplasm Metast... | DLI sensitized ... | - | Hadassah Medical Organization | |
| Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection | NCT01198236 | Invasive Fungal... | Itraconazole | 18 Years - 65 Years | Zhejiang University | |
| Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL | NCT02361346 | Non-Hodgkin's B... Leukemia, Lymph... Small Lymphocyt... Diffuse Large B... Blood Cancer Hematological M... | MT-3724 Phase 1 MT-3724 Phase 2 | 18 Years - | Molecular Templates, Inc. | |
| CAR-T Cellular Therapy for B Cell Malignancies Involved in CNS | NCT04287309 | Hematological M... | CAR-T cells | 3 Years - 75 Years | Zhejiang University | |
| Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies | NCT04305249 | Solid Tumor Hematological M... | ATG-017 ATG-017+Nivolum... | 18 Years - | Antengene Corporation | |
| Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies | NCT00446342 | B-lymphoid Mali... Chronic Lymphoc... Mantle Cell Lym... Multiple Myelom... | SNS-032 Injecti... | 18 Years - | Sunesis Pharmaceuticals | |
| A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients | NCT03241550 | Hematological M... | isavuconazonium... isavuconazonium... | 1 Year - 17 Years | Astellas Pharma Inc | |
| Effect of Body Mass on Acyclovir Pharmacokinetics | NCT01714180 | Hematological M... Pharmacokinetic... | 18 Years - | West Virginia University | ||
| Effects of Periodized and Autoregulated Resistance Training in Haematological Cancer Patients During the Treatent. | NCT04406285 | Fatigue Leukemia Lymphoma Physical Disabi... | Standard protoc... Periodic Resist... Standard protoc... Periodic Resist... | 18 Years - 64 Years | Federal University of Health Science of Porto Alegre | |
| Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis | NCT01860170 | Hematological M... | Cohort 1-Bortez... Cohort 2-Bortez... Cohort 3-Bortez... | 18 Years - | Spectrum Health Hospitals | |
| First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | NCT04067336 | Advanced Malign... Acute Myeloid L... Mixed Lineage L... Mixed Lineage A... Acute Leukemia ... Mixed Phenotype... | Ziftomenib | 18 Years - | Kura Oncology, Inc. | |
| PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients | NCT04243434 | Hematologic Dis... | Vincristine Sul... CHOP R-CHOP | 18 Years - | Acrotech Biopharma Inc. | |
| Ceritinib Rare Indications Study in ALK+ Tumors | NCT02465528 | Tumors With Abe... Anaplastic Larg... Inflammatory My... Glioblastoma | Ceritinib (LDK3... | 18 Years - | Novartis | |
| Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia | NCT05537896 | Hematological M... Neutropenia | Eravacycline | 18 Years - | West Virginia University | |
| Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies | NCT00446342 | B-lymphoid Mali... Chronic Lymphoc... Mantle Cell Lym... Multiple Myelom... | SNS-032 Injecti... | 18 Years - | Sunesis Pharmaceuticals | |
| A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation | NCT00894049 | Allograft Allogeneic Cell... Hematological M... Solid Tumor | reduced intensi... | 18 Years - 65 Years | Institut Paoli-Calmettes | |
| Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials | NCT02534649 | Solid Tumor Hematological M... | Newly obtained ... | 18 Years - | Institut Bergonié | |
| The Effect of Special Diets in Hematological Cancer Patients | NCT02880709 | Hematological M... | Special diet | 18 Years - | University of Copenhagen | |
| Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation | NCT01554254 | Cord Blood Tran... Hematologic Mal... Inherited Metab... | TXA127 | 6 Months - 20 Years | Tarix Pharmaceuticals | |
| Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19 | NCT04347226 | Solid Tumor Sars-CoV2 Hematological M... | BMS-986253 | 18 Years - | Columbia University | |
| Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia | NCT05537896 | Hematological M... Neutropenia | Eravacycline | 18 Years - | West Virginia University | |
| Systematic Symptom Identification With Disease Specific PROM to Assess Symptoms of Chronic GVHD in Outpatient Care in Patients Post HSCT | NCT04884204 | GVHD, Chronic Hematological M... | Lee Symptom Sca... | 18 Years - | Rigshospitalet, Denmark | |
| Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation | NCT01086735 | Hematological M... | donor lymphocyt... | 18 Years - 70 Years | Assistance Publique - Hôpitaux de Paris | |
| Systematic Symptom Identification With Disease Specific PROM to Assess Symptoms of Chronic GVHD in Outpatient Care in Patients Post HSCT | NCT04884204 | GVHD, Chronic Hematological M... | Lee Symptom Sca... | 18 Years - | Rigshospitalet, Denmark | |
| A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM) | NCT03875495 | Multiple Myelom... | Temferon | 18 Years - 70 Years | Genenta Science | |
| Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL | NCT02361346 | Non-Hodgkin's B... Leukemia, Lymph... Small Lymphocyt... Diffuse Large B... Blood Cancer Hematological M... | MT-3724 Phase 1 MT-3724 Phase 2 | 18 Years - | Molecular Templates, Inc. | |
| Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies | NCT05510089 | Hematological M... | Etoposide Cytarabine PEG-rhG-CSF | 18 Years - 75 Years | The Affiliated People's Hospital of Ningbo University | |
| Membrane Target Detection for Leukemia Treatment | NCT04841447 | Hematological M... | Study sample co... | 18 Years - | University of Missouri-Columbia |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
